Tianjing biology and Shiyao group reached strategic cooperation on the development of the project of recombinant GLP-1 Fc fusion protein

December 17, 2018 / Meitong news agency / -- Tianjing biology, a new biological drug R & D company focusing on tumor immunity and autoimmune disease treatment, jointly announced a strategic partnership with China's famous pharmaceutical group Shiyao Group Co., Ltd (01093 HK) The strategic cooperation includes that Tianjing biology grants the exclusive right to develop the long-term recombinant glp-1fc fusion protein (tg103) in China to Baike (Shandong) biopharmaceutical Co., Ltd., a wholly-owned subsidiary of Shiyao group Based on the terms of cooperation, Sinopharm group will pay Tianjing biology a down payment of 15 million yuan and a later milestone payment of 135 million yuan, and obtain the exclusive rights and interests of tg103 clinical development and future commercial promotion in China from Tianjing biology, and bear the development costs and pay sales commission to Tianjing biology Tg103 is an innovative recombinant human glucagon like peptide-1 (hglp-1) Fc fusion protein Tianjing biology has the patent right in China After obtaining the approval of clinical trials in China, it launched clinical research on type 2 diabetes Tg103 is based on the hyfc long-acting fusion protein platform technology Its molecular design has the characteristics of prolonging the half-life of GLP-1 in vivo According to the existing experimental data, tg103 can be administered subcutaneously once a week or once a fortnight, thus greatly improving the compliance of patients In preclinical studies and previous phase I clinical trials in Germany, tg103 also proved its superior safety, providing more possibilities for combination of drugs "We are very pleased to cooperate with a comprehensive pharmaceutical group with strong strength, such as Sinopharm group During the negotiation, we are very impressed by the highly professional and innovative ability of Sinopharm group Tianjing biology aims to provide innovative biotherapy solutions for patients all over the world Tg103 has outstanding innovation and safety We believe that through cooperation with Sinopharm group, we can more efficiently provide high-quality life for Chinese patients with type 2 diabetes and potential other patients The strategic cooperation with Sinopharm group is the third time since 2017 that Tianjing biology has developed our R & D pipeline products through exclusive authorization with famous biomedical enterprises at home and abroad These cooperation represents the full recognition of the partners on the independent R & D capability of Tianjing biology Tianjing biology will continue to work with potential global partners in an open and pragmatic manner to rapidly promote the listing of new biological drugs, so as to meet the prominent treatment needs of major diseases " Zhang zheru, President of Tianjing biology, said Dr Li Chunlei, director, executive president and chief scientist of Shiyao group, said: "as one of the most innovative pharmaceutical groups in China, Shiyao group is responsible for protecting people's livelihood and health We are very happy to cooperate with Tianjing bio, a highly innovative bio pharmaceutical company We believe that this cooperation is an important supplement to the innovative power of the product line of Shiyao group At the same time, we hope that through the development and commercialization of tg103, we can provide better and safer clinical solutions for patients with diseases, and also hope to have more cooperation with Tianjing biology in the future " About Tianjing biology: Tianjing biology has world-class R & D capability and experienced R & D team, and is committed to the research and development of first in class and best in class biological new drugs in the field of tumor immunity and immune inflammation At present, the company has two project sets: a Chinese pipeline set composed of several late stage clinical development products, and a global innovative biological medicine pipeline set with innovative potential that can enter the international clinical development Tianjing biology has submitted and is preparing to submit multiple ind applications for clinical trials in China and the United States, including a number of phase II and phase III studies Tianjing biology is rapidly becoming an end-to-end integrated biopharmaceutical company The company has been well recognized in the capital market, and successfully completed the c-round financing of 370 million US dollars in 18 months, becoming one of the largest Chinese innovative biotechnology companies in the c-round financing About Shiyao group: the predecessor enterprise of Shiyao Group Co., Ltd was founded in 1938 The group has total assets of 41 billion yuan and 25000 employees Listed companies in Hong Kong (01093 HK), with a market value of more than HK $100 billion, are the constituent stocks of Hang Seng Index and the first blue chip pharmaceutical stocks of Hang Seng Index in the past 50 years The Central Pharmaceutical Research Institute of Shiyao group is a national key laboratory recognized by the Ministry of science and technology of the people's Republic of China, and also a national engineering laboratory recognized by the national development and Reform Commission In addition, there are 4 R & D centers in California, New Jersey and Texas Shiyao group has more than 1700 scientific researchers and invests 1.2-1.5 billion yuan in new drug R & D every year At present, there are more than 200 innovative drug product projects, including 25 in the field of new target macromolecular biological drugs, cell immunotherapy stem cells, 30 in the field of small molecule new drugs, and 55 in the field of 3 categories of new drugs (now newly classified as 3 or 4 categories of drugs) Five products have been tested in the United States and 16 anda varieties have been approved Since the 11th five year plan, the group has undertaken 53 national science and technology projects, 24 provincial science and technology projects, and won 3 National Science and technology awards.